BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251001T130000
DTEND;TZID=America/New_York:20251001T140000
DTSTAMP:20260423T050810
CREATED:20250912T142319Z
LAST-MODIFIED:20250912T143403Z
UID:71518-1759323600-1759327200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Takeda - On-demand and Surgical Use of ADVATE® [Antihemophilic Factor (Recombinant)]
DESCRIPTION:Date: Wednesday\, October 1st\, 2025\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n \nWEBINAR TOPIC: \nOn-demand and Surgical Use of ADVATE® [Antihemophilic Factor (Recombinant)] \nOBJECTIVE: \nThis session will explore critical aspects of hemophilia A management\, focusing on the unique role of ADVATE in on-demand and perioperative settings. \nAUDIENCE: \nAll HTC Staff. \nSPEAKER: \nJessica Grandoni\, Pharm.D.\, BCPS\, was the Hemostatic Antithrombotic Stewardship Lead Pharmacist (HAT)\, and clinical pharmacy specialist\, at Brigham and Women’s Hospital in Boston\, Massachusetts. She is now a clinical pharmacy specialist at the Dana Farber Cancer Institute’s Anticoagulation Management Service. \nJessica has been involved in several committees and initiatives related to her practice interests of anticoagulation therapy and reversal\, heparin induced thrombocytopenia\, mechanical circulatory support\, drug formulary management and associated guidelines. She is involved in research\, education\, and publications with pharmacy\, hematology\, cardiology\, and the mechanical circulatory support division. She has published one of the top downloaded articles with the American Journal of Hematology and has presented at national and international conferences. Jessica earned her Doctor of Pharmacy degree from Massachusetts College of Pharmacy and Health Sciences University in Boston and completed an ASHP-accredited Post Graduate Year 1 residency at Beth Israel Deaconess Medical Center. She also completed an ASHP-accredited Post Graduate Year 2 cardiology residency at The University of California Davis Medical Center with a focus in anticoagulation and reversal.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-takeda-on-demand-and-surgical-use-of-advate-antihemophilic-factor-recombinant/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251015T140000
DTEND;TZID=America/New_York:20251015T150000
DTSTAMP:20260423T050810
CREATED:20250929T140734Z
LAST-MODIFIED:20250929T140911Z
UID:71627-1760536800-1760540400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Octapharma - Prophylaxis in VWD: Iron as a Metric of Success at Healing
DESCRIPTION:Date: Wednesday\, October 15th\, 2025\nTime: 2:00pm – 3:00pm ET \n \n  \n  \n \nWEBINAR TOPIC: \nProphylaxis in VWD: Iron as a Metric of Success at Healing. \nWEBINAR SUMMARY: \nA presentation on rethinking prophylaxis in VWD through a lens of healing and iron status. \nThis presentation explores a multidimensional approach to bleeding disorders\, with a focus on von Willebrand Disease (VWD)\, the evolving role of prophylaxis\, and iron deficiency as a measurable indicator of treatment success. By reframing bleeding disorders as healing disorders\, we challenge traditional paradigms and highlight the importance of patient-centered care. \nThrough clinical insights and emerging data\, we examine how iron status can serve as a proxy for bleeding control\, and how prophylactic strategies are reshaping outcomes across all types of VWD. This session invites clinicians\, researchers\, and educators to consider new metrics and models that better reflect the lived experiences of patients and the true impact of therapeutic interventions. \nAUDIENCE: \nAll HTC Staff. \nSPEAKER: \nAmber Federizo\, DNP \nBorn and raised in the rural heart of Nevada\, she has long been driven by a deep commitment to serving those who are often overlooked or underserved. For over a decade\, she provided compassionate diagnosis and treatment to patients of all ages at Nevada’s Hemophilia Treatment Center (HTC)\, with a particular focus on addressing the unique challenges faced by women in the bleeding disorders community. Her unwavering dedication and authentic approach have brought light and hope to vulnerable populations both domestically and internationally. \nIn recognition of her impactful work\, Amber was honored in 2018 as the Humanitarian of the Year by the National Hemophilia Foundation (now known as the National Bleeding Disorders Foundation). Through research\, education\, and advocacy\, she continues to forge new pathways and expand opportunities for individuals and families affected by bleeding disorders.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-octapharma-prophylaxis-in-vwd-iron-as-a-metric-of-success-at-healing/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251023T150000
DTEND;TZID=America/New_York:20251023T160000
DTSTAMP:20260423T050810
CREATED:20250924T184603Z
LAST-MODIFIED:20251001T160641Z
UID:71621-1761231600-1761235200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Genentech - Revolutionizing Hemophilia A Care: Nurses’ Insights on the First Subq Prophy for Hem A
DESCRIPTION:Date: Thursday\, October 23rd\, 2025\nTime: 3:00pm – 4:00pm ET \n \n  \n  \n  \n \nWEBINAR TITLE: \nRevolutionizing Hemophilia A Patient Care: Nurses’ Insights on the First Subcutaneous Prophylaxis Treatment for Hemophilia A. \nDESCRIPTION: \nPlease join us for an engaging discussion featuring nurses Jennifer Maahs\, RN\, PNP\, MSN and Joseph Stanco\, MSN\, DNP\, CCRC as they share their perspectives on the evolution of hemophilia A management. We’ll celebrate the personal and collective experiences of nurses and their crucial role in the patient’s treatment journey with the first subcutaneous prophylaxis treatment for hemophilia A. Test your knowledge with trivia while discovering the impact of a treatment with over a decade of clinical trial experience\, as the presentation highlights expert clinical practice insights\, pivotal efficacy and safety data\, and long-term outcomes\, including data in infants. Please bring your questions to have them answered live in the Q&A following the program. \nAUDIENCE: \nAll HTC Staff. \nSPEAKERS: \n\nJennifer Maahs\, RN\, PNP\, MSN – Jennifer Maahs is a Pediatric Nurse Practitioner at the Indiana Hemophilia and Thrombosis Center\, a role she has held since 1993. She earned her MS in Nursing as a Pediatric Nurse Practitioner from Indiana University and a Bachelor of Science in Nursing from The Ohio State University. Her expertise lies in research\, education\, and patient care for hemophilia\, hemostasis\, and thrombosis-related complications. Ms. Maahs is actively involved in developing and implementing educational programs for medical care providers in the bleeding disorder community\, has served on numerous committees and advisory boards\, and is currently the US representative for the World Federation of Hemophilia.\nJoseph Stanco\, MSN\, DNP\, CCRC – Joseph Stanco is a Doctor of Nursing Practice. As a family nurse practitioner he cares for children and adults with bleeding disorders as well as leading various research as the nurse coordinator of the Northwell Health Hemostasis and Thrombosis Center. Beyond his caring for patients\, Joe is the president Hemostasis and Thrombosis Nursing Association\, Executive Committee Member of the New England Hemophilia Region\, New England representative of the NBDF Nursing Working Group.\nMost recently Joe was awarded Nurse of the year at the 2025 NBDF Bleeding Disorders Conference.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-genentech-revolutionizing-hemophilia-a-care-nurses-insights-on-the-first-subq-prophy-for-hem-a/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251030T140000
DTEND;TZID=America/New_York:20251030T150000
DTSTAMP:20260423T050810
CREATED:20250912T144235Z
LAST-MODIFIED:20250912T144438Z
UID:71524-1761832800-1761836400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Novo Nordisk - Alhemo (concizumab-mtci): A new option for patients living with hemophilia
DESCRIPTION:Date: Thursday\, October 30th\, 2025\nTime: 2:00pm – 3:00pm ET \n \n  \n  \n  \n \nWEBINAR TOPIC: \nAlhemo (concizumab-mtci): A new option for patients living with hemophilia. \nOBJECTIVE: \nTo provide an update on prescribing information of the recently FDA-approved indication in patients with hemophilia A or B without inhibitors\, and supporting data from the explorer8 trial. \nAUDIENCE: \nAll HTC Staff. \nSPEAKER: \nRyan Rodriguez\, PharmD\, MS\, BCPS\, is a Medical Liaison for rare blood disorders at Novo Nordisk covering the Midwest. His responsibilities include learning from and sharing medical information with clinicians who treat patients with hemophilia and other bleeding disorders\, aligning with his passion for evidence-based patient care. \nPrior to joining Novo Nordisk\, Ryan earned his PharmD degree from the University of Florida\, and then served as Clinical Associate Professor at the University of Illinois Chicago College of Pharmacy\, where he also earned his Master’s degree in epidemiology. Throughout his career\, Ryan has been involved in medical communications\, evidence generation and publication\, and formulary management for various public and private entities.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-novo-nordisk-alhemo-concizumab-mtci-a-new-option-for-patients-living-with-hemophilia/
CATEGORIES:Members Only,Webinar
END:VEVENT
END:VCALENDAR